Synaptic plasticity and neurodegenerative diseases: Implications for treatment.

Jessica Miletic*

Department of Psychology and Neuroscience, Temple University, USA

Introduction

Synaptic plasticity, the ability of synapses to strengthen or weaken over time in response to activity, plays a crucial role in learning, memory, and overall cognitive function. It is a fundamental mechanism underlying the adaptability of the nervous system. In the context of neurodegenerative diseases, disruptions in synaptic plasticity contribute significantly to cognitive decline and neuronal dysfunction. Understanding these mechanisms offers potential therapeutic avenues for treating conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) [1].

Neurodegenerative diseases are characterized by the progressive loss of neurons and synaptic connections, leading to functional impairments. Synaptic dysfunction often precedes neuronal death, highlighting the importance of synaptic plasticity in disease pathology. For instance, in Alzheimer's disease, early synaptic failure due to amyloid-beta toxicity impairs long-term potentiation (LTP), a process essential for memory formation. Similarly, tau protein aggregates disrupt synaptic signaling, exacerbating cognitive deficits [2].

In Parkinson's disease, degeneration of dopaminergic neurons in the substantia nigra affects synaptic plasticity in the basal ganglia, leading to motor impairments. Dopamine is critical for modulating synaptic strength, and its depletion results in altered plasticity patterns, contributing to both motor and non-motor symptoms. Studies have shown that enhancing synaptic plasticity through pharmacological interventions or neurostimulation techniques may help restore functional connectivity in affected neural circuits [3].

Huntington's disease, a genetic disorder characterized by abnormal movements and cognitive decline, also involves synaptic dysfunction. Mutant huntingtin protein disrupts synaptic plasticity by impairing glutamatergic transmission and reducing synaptic resilience. Targeting synaptic pathways with neuroprotective strategies, such as brain-derived neurotrophic factor (BDNF) therapy, holds promise for mitigating synaptic damage in this disorder [4].

ALS, a disease that affects motor neurons, is associated with synaptic degeneration in both cortical and spinal circuits. The excitotoxicity hypothesis suggests that excessive glutamate activity contributes to synaptic failure and neuronal death. Approaches aimed at modulating excitatory and inhibitory balance through pharmacological agents or gene therapy could provide therapeutic benefits by preserving synaptic function [5].

Given the central role of synaptic plasticity in neurodegeneration, various treatment strategies are being explored to enhance synaptic resilience. Pharmacological approaches targeting neurotransmitter systems, such as cholinergic, glutamatergic, and dopaminergic pathways, have shown potential in restoring synaptic function. For instance, NMDA receptor modulators have been investigated for their ability to enhance synaptic strength in Alzheimer's disease models [6].

Neurotrophic factors, such as BDNF and nerve growth factor (NGF), are critical for maintaining synaptic integrity. Experimental therapies involving BDNF administration or gene therapy to upregulate neurotrophic signaling have demonstrated neuroprotective effects in animal models of neurodegenerative diseases. However, challenges related to delivery methods and long-term efficacy need to be addressed for clinical application [7].

Non-pharmacological interventions, including transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS), have been explored for their potential to modulate synaptic plasticity. TMS, for instance, has shown promise in enhancing cortical excitability and improving cognitive function in Alzheimer's and Parkinson's disease patients. Similarly, DBS of the basal ganglia has been effective in alleviating motor symptoms in Parkinson’s disease by restoring disrupted neural circuits [8].

Lifestyle factors such as physical exercise, cognitive training, and dietary interventions also play a role in promoting synaptic plasticity. Exercise has been shown to increase BDNF levels, enhance synaptic connectivity, and delay cognitive decline. Likewise, cognitive training programs targeting memory and executive function can reinforce synaptic networks, potentially slowing disease progression [9].

Future research should focus on developing combinatorial therapies that integrate pharmacological, neurotrophic, and neuromodulation strategies to optimize synaptic plasticity restoration. Advances in precision medicine and gene therapy hold promise for targeting specific molecular pathways

***Correspondence to:** Jessica Miletic, Department of Psychology and Neuroscience, Temple University, USA, E mail: jessica.miletic@temple.edu

Received: 3-Feb-2025, Manuscript No. aacnj-25-161442; **Editor assigned:** 5-Feb-2025, PreQC No. aacnj-25-161442 (PQ); **Reviewed:** 15-Feb-2025, QC No. aacnj-25-161442; **Revised**: 21-Feb-2025, Manuscript No. aacnj-25-161442 (R); **Published**: 28-Feb-2025, DOI:10.35841/aacnj-8.1.249.

Citation: *Miletic J. Synaptic plasticity and neurodegenerative diseases: Implications for treatment. J Cogn Neurosci. 2025;8(1):249.*

involved in synaptic dysfunction. Additionally, early detection of synaptic changes through advanced imaging and biomarker identification could enable timely interventions before irreversible neuronal loss occurs [10].

Conclusion

In conclusion, synaptic plasticity is a key factor in the pathophysiology of neurodegenerative diseases. Understanding its mechanisms and developing targeted interventions offer promising therapeutic opportunities. While significant progress has been made in preclinical and clinical research, continued efforts are needed to translate these findings into effective treatments that improve quality of life for individuals affected by neurodegenerative conditions.

References

1. Pilato F, Profice P, Ranieri F, et al. Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques. Mol Neurobiol. 2012;46:563-71.
2. Keifer J. Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease. J Neurosci Res. 2022;100(4):979-91.
3. Morris GP, Clark IA, Zinn R, et al. Microglia: A new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem. 2013;105:40-53.
4. Mattson MP, Camandola S. NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107(3):247-54.
5. Dejanovic B, Sheng M, Hanson JE. Targeting synapse function and loss for treatment of neurodegenerative diseases. Nat Rev Drug Discov. 2024;23(1):23-42.
6. Sebastião AM, Colino-Oliveira M, Assaife-Lopes N, et al. Lipid rafts, synaptic transmission and plasticity: Impact in age-related neurodegenerative diseases. Neuropharmacol. 2013;64:97-107.
7. Kopeikina E, Ponomarev ED. The role of platelets in the stimulation of neuronal synaptic plasticity, electric activity, and oxidative phosphorylation: possibilities for new therapy of neurodegenerative diseases. Front Cell Neurosci. 2021;15:680126.
8. Weerasinghe-Mudiyanselage PD, Ang MJ, Kang S, et al. Structural plasticity of the hippocampus in neurodegenerative diseases. Int J Mol Sci. 2022;23(6):3349.
9. Calabresi P, Centonze D, Gubellini P, et al. Synaptic transmission in the striatum: From plasticity to neurodegeneration. Progress in neurobiology. 2000;61(3):231-65.
10. Peng L, Bestard-Lorigados I, Song W. The synapse as a treatment avenue for Alzheimer's Disease. Mol Psychiatry. 2022;27(7):2940-9.

Citation: *Miletic J. Synaptic plasticity and neurodegenerative diseases: Implications for treatment. J Cogn Neurosci. 2025;8(1):249.*